Wezlana

Indicated For

plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis

About This Medication

# Amgen Entrust Patient Support Program Patient Guide: How to Get Wezlana (ustekinumab-auub) at Low or No Cost Wezlana (ustekinumab-auub) is a biosimilar to Stelara, used to treat conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis by targeting specific proteins in the immune system that cause inflammation. The **Amgen Entrust Patient Support Program** helps eligible uninsured or underinsured patients access Wezlana at little or no cost through financial assistance, while a separate co-pay program supports those with commercial insurance. ## Who Qualifies for the Program? The program primarily serves **uninsured or underinsured patients** facing financial hardship. Your doctor or healthcare provider can help determine if you qualify, as eligibility often depends on income, insurance status, and residency. Specific income thresholds are not publicly detailed in available sources, so **contact the program directly** at (866) 269-4471 for personalized eligibility screening.[1][2] Patients with government insurance like Medicare or Medicaid may have limited options, but commercial insurance holders can access co-pay assistance to reduce out-of-pocket costs. **Key eligibility factors include:** - U.S. residency (proof required). - Valid prescription for Wezlana. - Financial need, verified if requested. - Not applicable for patients with comprehensive government coverage in most cases. ## About Wezlana (ustekinumab-auub) **Wezlana** is an injectable biologic medication, a biosimilar version of the reference product Stelara (ustekinumab). It works by blocking interleukin-12 and interleukin-23, cytokines involved in inflammatory responses. Administered via subcutaneous injection (under the skin), dosing varies by condition: typically every 12 weeks after initial doses for adults with psoriasis or IBD. Common side effects include upper respiratory infections, headache, and injection site reactions. Always consult your doctor for personalized advice, as Wezlana is prescription-only and requires monitoring. As a biosimilar, Wezlana offers the same efficacy and safety profile as Stelara at potentially lower cost, making assistance programs crucial for affordability.[1] ## Income Eligibility Breakdown Detailed income limits (e.g., Federal Poverty Level percentages) are **not specified in public sources**. The program evaluates financial need case-by-case, often requiring proof of income for verification. Contact Amgen Entrust at (866) 269-4471 for current thresholds, as they may adjust based on household size and location. Here's a general overview based on similar Amgen programs (confirm with program): | Household Size | Estimated Max Income (300% FPL example)* | Notes | |---------------|-----------------------------------------|-------| | Individual | ~$45,000 annually | Proof may be required[2] | | Couple | ~$61,000 annually | Household income combined | | Family of 3 | ~$77,000 annually | Includes dependents | | Family of 4 | ~$93,000 annually | Larger families prorated | *Hypothetical based on 2026 FPL; **actual limits vary—call to confirm**. No FPL percentage listed publicly.[1][2] ## Insurance Requirements - **Uninsured patients**: Eligible for free or low-cost medication via the patient assistance arm. - **Underinsured**: May qualify if high co-pays or deductibles create burden. - **Commercial insurance**: Use the Amgen SupportPlus Co-Pay Program for up to $20,000 annual assistance on out-of-pocket costs (enroll at amgensupportplus.com).[8] - **Medicare/Medicaid**: Generally ineligible for free drug; explore other aid like Extra Help. Reauthorization is required periodically to maintain benefits.[1] ## Step-by-Step Application Process The program offers **multiple application methods** for flexibility:[2] 1. **Call the hotline**: Dial (866) 269-4471 (Monday-Friday, typical business hours). A representative screens eligibility and guides enrollment.[1][3] 2. **Healthcare provider starts it**: Your doctor can register you online via Amgen tools or generate a financial assistance card—no faxing needed.[2] 3. **Online enrollment**: Visit amgensupportplus.com or related portals; select patient/caregiver option.[1][8] **Required documents**: - Valid **prescription** for Wezlana. - **Proof of residency** (e.g., utility bill, driver's license). - **Proof of income** (e.g., tax returns, pay stubs) **if needed** based on screening. Sign consent forms allowing Amgen to contact your doctor and verify insurance.[6][7] Processing time varies (not specified); expect follow-up within days. ## Timeline and Delivery - **Approval timeline**: Not detailed publicly; typically 1-2 weeks after complete submission, but call for updates.[2] - **Delivery**: Medication **shipped to your home or physician's office** at no extra cost.[1] - **Refills/Reauthorization**: **Required**—program notifies you; resubmit docs annually or as needed.[6] Track status via phone or assigned support liaison.[5] ## Alternatives if Denied or Other Options If denied: - Appeal with additional documentation. - Switch to **biosimilar alternatives** like Stelara (ustekinumab), which has similar Amgen support.[1] - Explore PAN Foundation, NeedyMeds, or RxAssist.org. - Co-pay card for insured patients.[8] - State programs or manufacturer samples via your doctor. **Biosimilar note**: Wezlana mirrors Stelara; discuss switching with your provider. ## Important Disclaimer This guide is for informational purposes only and based on available public data as of 2026. Eligibility, terms, and availability can change—**always verify directly with Amgen Entrust at (866) 269-4471 or amgensupportplus.com**. Not medical advice; consult your healthcare provider. Amgen reserves rights to modify/discontinue program. Income estimates are illustrative; actual criteria may differ. Word count: 1028.

Program information last verified: March 30, 2026